Surgery and radiotherapy are key elements to the treatment of skull-base chondrosarcomas; however, there is currently no consensus regarding whether or not adjuvant radiotherapy has to be administered. This study searched the EMBASE, Cochrane, and PubMed databases for clinical studies evaluating the long-term prognosis of surgery with or without adjuvant radiotherapy. After reviewing the search results, a total of 22 articles were selected for this review. A total of 1388 patients were included in this cohort, of which 186 received surgery only. With mean follow-up periods ranging from 39.1 to 86 months, surgical treatment provided progression-free survival (PFS) rates ranging from 83.7 to 92.9% at 3 years, 60.0 to 92.9% at 5 years, and 58.2 to 64.0% at 10 years. Postoperative radiotherapy provides PFS rates ranging between 87 and 96.2% at 3 years, 57.1 and 100% at 5 years, and 67 and 100% at 10 years. Recurrence rates varied from 5.3% to 39.0% in the surgery-only approach and between 1.5% and 42.90% for the postoperative radiotherapy group. When considering prognostic variables, higher age, brainstem/optic apparatus compression, and larger tumor volume prior to radiotherapy were found to be significant factors for local recurrence.
手术与放疗是颅底软骨肉瘤治疗的关键手段，但目前对于是否需行辅助放疗尚未达成共识。本研究检索了EMBASE、Cochrane及PubMed数据库中评估手术联合或不联合辅助放疗长期预后的临床研究。经筛选后共纳入22篇文献进行分析。本队列共包含1388例患者，其中186例仅接受手术治疗。在平均39.1至86个月的随访期内，单纯手术治疗组的3年无进展生存率为83.7%-92.9%，5年为60.0%-92.9%，10年为58.2%-64.0%；术后放疗组的3年无进展生存率为87%-96.2%，5年为57.1%-100%，10年为67%-100%。单纯手术组的复发率为5.3%-39.0%，术后放疗组为1.5%-42.90%。在预后因素分析中，高龄、脑干/视神经受压以及放疗前较大肿瘤体积被证实是局部复发的重要影响因素。
Skull-Base Chondrosarcoma: A Systematic Review of the Role of Postoperative Radiotherapy
肿瘤(癌症)患者之家